August 8, 2018 08:30 AM EDTUpdated 10:59 AM

First-in-human studies in sight, SQZ's cell therapy tech wins over a diverse group of investors in $72M round

Amber Tong

Having steadily built out the preclinical data to cement its cell therapy platform and sorted out the technicalities, SQZ Biotech has raised $72 million to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

First-in-human studies in sight, SQZ's cell therapy tech wins over a diverse group of investors in $72M round

Amber Tong

Sign up to read this article for free.

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Altos Labs buys anti-aging startup Dorian Therapeutics

Genentech expands deal with molecular glue biotech Orionis for $105M upfront

Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study

Updated: Trump administration reveals 'most favored nation' drug price country targets

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

First-in-hu­man stud­ies in sight, SQZ's cell ther­a­py tech wins over a di­verse group of in­vestors in $72M round

Amber Tong

Sign up to read this article for free.

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

First-in-human studies in sight, SQZ's cell therapy tech wins over a diverse group of investors in $72M round

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Altos Labs buys anti-aging startup Dorian Therapeutics

Genentech expands deal with molecular glue biotech Orionis for $105M upfront

Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study

Updated: Trump administration reveals 'most favored nation' drug price country targets

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?